In our study, it is possible that naïve T cells had already encountered tumor-derived EVs expressing PD-L1 in a therapeutic model before the treatment started, resulting in suppressed T cells and unresponsiveness to the checkpoint therapy. This evidence concerns the gene CD274 and neoplasm.